T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Registration Number
- NCT02073916
- Lead Sponsor
- Jenny C. Chang, MD
- Brief Summary
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.
- Detailed Description
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of each 1-week cycle and T-DM1 on Day 1 of each 3-week cycle. Patients with take Lapatinib orally daily. Patients will receive the study treatment for 12 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Documented metastatic Her2 over-expressed breast cancer.
- Age ≥ 18 years Patients must have received at least two prior therapies for their malignant disease.
- Patients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE)
- Adequate organ function (cardiac ejection fraction of ≥ 45%),
- CBC not less than .75 of institutional lower limit.
- Patients must have adequate liver function: AST and ALT < 2.5 X upper limit of normal, alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis Bilirubin < 1.5 mg/dL
- Patients must have adequate renal function: creatinine <1.5 mg/dL is recommended; however, institutional norms are acceptable.
- Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential
- Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed). Contraception method must be used during treatment and for three months after completing treatment Signed informed consent form (ICF)
- Any medical or psychiatric condition that would prevent informed consent or limit survival to less than 4 weeks.
- Absolute QT interval of >460 msec in the presence of potassium >4.0mEq/L and Magnesium >1.8mg/dl.
- Patient with HIV and post- transplant associated lymphoproliferative disorders.
- Patient with concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of Trastuzumab Emtansine, Lapatinib or Abraxane.
- Pregnant or lactating women.
- Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, lapatinib, abraxane, or their components.
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
- Subjects with ulcerative colitis are also excluded.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description T-DM1 + Lapatinib + Abraxane Abraxane T-DM1 with Laptinib followed by Abraxane T-DM1 + Lapatinib + Abraxane T-DM1 T-DM1 with Laptinib followed by Abraxane T-DM1 + Lapatinib + Abraxane Lapatinib T-DM1 with Laptinib followed by Abraxane
- Primary Outcome Measures
Name Time Method Maximum Tolerable Dose approximately 16 weeks Maximum tolerated dose (MTD) of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer.
- Secondary Outcome Measures
Name Time Method Dose Limiting Toxicities From date of randomization through study follow up (approximately 16 weeks) Describe the dose-limiting toxicity (DLT) associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0.
Anti-tumor activity through imaging approximately 16 weeks from randomization Document anti-tumor activity of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer as assessed by RECIST 1:1 criteria
Plasma pharmacokinetics and pharmacodynamic effect of treatment combination Day 1 and 1,2,4,and 24hours Determine the plasma pharmacokinetics of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane.
Measure toxicities associated with treatment combination From date of randomization through study follow up (approximately 16 weeks) Describe and measure other toxicities associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0.
Trial Locations
- Locations (1)
Houston Methodist Hospital
🇺🇸Houston, Texas, United States